IMMUNE Pharmaceuticals, a developer of monoclonal antibodies, and Yeda, the technology transfer company of the Weizmann Institute of Science, announced a broad collaboration to develop antibody therapeutics focusing on the development of new cancer treatments. IMMUNE Pharmaceuticals, an Israel and US based biopharmaceutical company, focuses on the development of next generation monoclonal antibodies addressing the treatment of cancer and inflammatory diseases.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
UK Adopts Israeli Counter-Drone Technology
April 25, 2024
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Facebook comments